That's my point. If the assets are as good as we've been told, then it shouldn't be a problem to interest any major player. Amgen knows all the details and so far nothing from them.
If the industry isn't seeing anything positive at this stage then I would stop right now. If the Azer-Cel data and the Bile-Duct data aren't convincing for big pharma at this stage then why should any fund invest when it is crystal clear that it is more smoke and mirrors instead of a breakthrough treatment.
The IMUverse must be acknowledged by the real big Pharmaverse. If not, close the business.
IMU Price at posting:
1.6¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)